| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 20 | 2023 | 1502 | 2.560 |
Why?
|
| Genome-Wide Association Study | 11 | 2024 | 333 | 1.620 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2017 | 628 | 1.360 |
Why?
|
| Quantitative Trait Loci | 2 | 2017 | 77 | 0.980 |
Why?
|
| Colorectal Neoplasms | 5 | 2018 | 441 | 0.960 |
Why?
|
| DNA Copy Number Variations | 2 | 2013 | 28 | 0.820 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 807 | 0.810 |
Why?
|
| Dance Therapy | 1 | 2019 | 5 | 0.700 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 40 | 0.640 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2021 | 767 | 0.630 |
Why?
|
| Computer Simulation | 3 | 2017 | 362 | 0.620 |
Why?
|
| Carcinoma, Lobular | 2 | 2008 | 3 | 0.590 |
Why?
|
| Receptors, Estrogen | 4 | 2021 | 156 | 0.580 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2008 | 29 | 0.580 |
Why?
|
| Registries | 1 | 2018 | 335 | 0.570 |
Why?
|
| CpG Islands | 4 | 2024 | 97 | 0.570 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 213 | 0.560 |
Why?
|
| Carcinoma | 2 | 2015 | 96 | 0.530 |
Why?
|
| Receptors, Somatomedin | 1 | 2015 | 3 | 0.510 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2015 | 3 | 0.510 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2015 | 23 | 0.510 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2015 | 70 | 0.490 |
Why?
|
| Genetic Variation | 1 | 2017 | 387 | 0.490 |
Why?
|
| Middle Aged | 20 | 2022 | 10129 | 0.470 |
Why?
|
| Exercise | 1 | 2019 | 613 | 0.460 |
Why?
|
| Humans | 39 | 2024 | 37093 | 0.460 |
Why?
|
| Female | 28 | 2023 | 20969 | 0.450 |
Why?
|
| Aged | 16 | 2021 | 6741 | 0.440 |
Why?
|
| DNA Methylation | 6 | 2024 | 325 | 0.420 |
Why?
|
| Adenoma | 1 | 2013 | 89 | 0.400 |
Why?
|
| Connexin 43 | 5 | 1999 | 38 | 0.400 |
Why?
|
| Colon | 1 | 2012 | 103 | 0.390 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 186 | 0.370 |
Why?
|
| Adiposity | 2 | 2023 | 154 | 0.370 |
Why?
|
| Adult | 13 | 2021 | 11712 | 0.350 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 19 | 0.330 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 935 | 0.320 |
Why?
|
| Mammary Glands, Human | 2 | 2018 | 39 | 0.300 |
Why?
|
| Hawaii | 6 | 2022 | 1929 | 0.300 |
Why?
|
| Gap Junctions | 2 | 1999 | 38 | 0.300 |
Why?
|
| Mutation | 3 | 2020 | 1095 | 0.290 |
Why?
|
| Drosophila Proteins | 3 | 2005 | 171 | 0.290 |
Why?
|
| Repressor Proteins | 2 | 2005 | 249 | 0.270 |
Why?
|
| Transcription Factors | 3 | 2005 | 681 | 0.260 |
Why?
|
| DNA-Binding Proteins | 3 | 2005 | 539 | 0.260 |
Why?
|
| DNA, Neoplasm | 4 | 2012 | 92 | 0.260 |
Why?
|
| Phenotype | 5 | 2023 | 689 | 0.260 |
Why?
|
| Gene Expression | 3 | 2018 | 674 | 0.240 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 180 | 0.230 |
Why?
|
| Alleles | 3 | 2017 | 321 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 275 | 0.220 |
Why?
|
| Case-Control Studies | 6 | 2023 | 1130 | 0.220 |
Why?
|
| Cyanobacteria | 1 | 2023 | 23 | 0.220 |
Why?
|
| Bacterial Toxins | 1 | 2023 | 44 | 0.220 |
Why?
|
| Intra-Abdominal Fat | 1 | 2023 | 45 | 0.210 |
Why?
|
| Oncogene Protein pp60(v-src) | 2 | 1999 | 10 | 0.210 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 4 | 0.200 |
Why?
|
| Pancreas | 1 | 2021 | 35 | 0.200 |
Why?
|
| Receptors, Progesterone | 1 | 2021 | 81 | 0.190 |
Why?
|
| Postmenopause | 1 | 2021 | 128 | 0.190 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 145 | 0.190 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 11 | 0.190 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 893 | 0.190 |
Why?
|
| Relaxin | 1 | 2020 | 10 | 0.190 |
Why?
|
| Hypothyroidism | 1 | 2020 | 18 | 0.190 |
Why?
|
| Cohort Studies | 5 | 2024 | 1492 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 24 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 190 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 75 | 0.180 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 37 | 0.180 |
Why?
|
| Incidence | 2 | 2022 | 922 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 643 | 0.180 |
Why?
|
| Anthropometry | 1 | 2019 | 97 | 0.170 |
Why?
|
| Pilot Projects | 2 | 2019 | 661 | 0.170 |
Why?
|
| Vimentin | 1 | 2018 | 37 | 0.160 |
Why?
|
| MicroRNAs | 1 | 2024 | 426 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 306 | 0.160 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 111 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2015 | 63 | 0.160 |
Why?
|
| Protein Isoforms | 1 | 2018 | 130 | 0.160 |
Why?
|
| Genetic Loci | 2 | 2015 | 90 | 0.160 |
Why?
|
| Gene Dosage | 3 | 2015 | 75 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 128 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2018 | 31 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 98 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 1996 | 132 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 123 | 0.150 |
Why?
|
| Young Adult | 3 | 2019 | 4268 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2017 | 129 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 626 | 0.140 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 133 | 0.140 |
Why?
|
| Prognosis | 4 | 2021 | 739 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 7 | 0.130 |
Why?
|
| Fanconi Anemia | 1 | 2015 | 12 | 0.130 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2015 | 34 | 0.130 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 1995 | 9 | 0.130 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2015 | 17 | 0.130 |
Why?
|
| RNA, Neoplasm | 1 | 2015 | 26 | 0.130 |
Why?
|
| Quality of Life | 1 | 2019 | 481 | 0.130 |
Why?
|
| Risk Factors | 4 | 2023 | 3562 | 0.130 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2005 | 69 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 26 | 0.130 |
Why?
|
| Computational Biology | 1 | 2017 | 293 | 0.120 |
Why?
|
| Qb-SNARE Proteins | 1 | 2014 | 2 | 0.120 |
Why?
|
| Gene Frequency | 2 | 2015 | 195 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2015 | 195 | 0.120 |
Why?
|
| Male | 9 | 2023 | 20025 | 0.120 |
Why?
|
| Flow Cytometry | 2 | 2005 | 399 | 0.120 |
Why?
|
| Phosphorylation | 6 | 2019 | 928 | 0.110 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 67 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 251 | 0.110 |
Why?
|
| Allelic Imbalance | 1 | 2013 | 4 | 0.110 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 59 | 0.110 |
Why?
|
| Odds Ratio | 3 | 2021 | 534 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 43 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2018 | 1908 | 0.110 |
Why?
|
| Drosophila | 2 | 2004 | 144 | 0.110 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 13 | 0.100 |
Why?
|
| Obesity | 2 | 2023 | 1067 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 25 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 55 | 0.100 |
Why?
|
| Smoking | 1 | 2018 | 940 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 80 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2012 | 142 | 0.100 |
Why?
|
| Choline | 1 | 2012 | 59 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2005 | 295 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2379 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 214 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 182 | 0.090 |
Why?
|
| Protein Binding | 2 | 2005 | 972 | 0.090 |
Why?
|
| Animals | 10 | 2019 | 15081 | 0.090 |
Why?
|
| Peptide Mapping | 3 | 1999 | 19 | 0.080 |
Why?
|
| Epigenesis, Genetic | 2 | 2024 | 219 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 481 | 0.080 |
Why?
|
| Nicotine | 2 | 2024 | 257 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 441 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2024 | 1378 | 0.080 |
Why?
|
| Recurrence | 2 | 2021 | 131 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 974 | 0.080 |
Why?
|
| Age Factors | 1 | 2011 | 1033 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1999 | 189 | 0.070 |
Why?
|
| Glutathione Transferase | 2 | 2005 | 88 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 623 | 0.070 |
Why?
|
| Mammography | 2 | 2018 | 188 | 0.070 |
Why?
|
| Risk | 2 | 2018 | 267 | 0.070 |
Why?
|
| Japan | 2 | 2018 | 305 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2005 | 17 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 50 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2018 | 2231 | 0.060 |
Why?
|
| Body Size | 1 | 2005 | 32 | 0.060 |
Why?
|
| Dimerization | 1 | 2005 | 112 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 113 | 0.060 |
Why?
|
| Alternative Splicing | 1 | 2005 | 85 | 0.060 |
Why?
|
| Cell Separation | 1 | 2005 | 93 | 0.060 |
Why?
|
| DNA | 2 | 2005 | 574 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2005 | 172 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2005 | 111 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 208 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 408 | 0.060 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 23 | 0.060 |
Why?
|
| Genotype | 2 | 2018 | 730 | 0.060 |
Why?
|
| Hydroxycholesterols | 1 | 2023 | 12 | 0.060 |
Why?
|
| Longevity | 1 | 2005 | 147 | 0.060 |
Why?
|
| Insulin | 1 | 2005 | 236 | 0.060 |
Why?
|
| Marine Toxins | 1 | 2023 | 13 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2024 | 86 | 0.060 |
Why?
|
| Microcystins | 1 | 2023 | 8 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 1999 | 52 | 0.050 |
Why?
|
| Testosterone | 1 | 2023 | 193 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 578 | 0.050 |
Why?
|
| Fibroblasts | 2 | 2005 | 272 | 0.050 |
Why?
|
| Phylogeny | 1 | 2005 | 644 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2021 | 11 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2021 | 5 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2021 | 18 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 515 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 935 | 0.050 |
Why?
|
| Base Sequence | 3 | 2004 | 997 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 1742 | 0.050 |
Why?
|
| Cholesterol | 1 | 2021 | 205 | 0.040 |
Why?
|
| Cell Division | 2 | 2015 | 307 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 2014 | 188 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2005 | 1198 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 311 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2015 | 1369 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 1999 | 91 | 0.040 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 325 | 0.040 |
Why?
|
| Phosphopeptides | 2 | 1996 | 4 | 0.040 |
Why?
|
| Spodoptera | 2 | 1996 | 13 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 1999 | 218 | 0.040 |
Why?
|
| Smad7 Protein | 1 | 2018 | 5 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 65 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 854 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1997 | 1568 | 0.040 |
Why?
|
| src Homology Domains | 1 | 1997 | 12 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 5913 | 0.040 |
Why?
|
| Tyrosine | 1 | 1997 | 118 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 197 | 0.040 |
Why?
|
| Rats | 3 | 1999 | 3483 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 474 | 0.040 |
Why?
|
| United States | 2 | 2018 | 4223 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1996 | 40 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2019 | 339 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 617 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 601 | 0.030 |
Why?
|
| Baculoviridae | 1 | 1995 | 14 | 0.030 |
Why?
|
| Cell Fractionation | 1 | 1995 | 30 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 93 | 0.030 |
Why?
|
| Metabolome | 1 | 2015 | 53 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 37 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 57 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 103 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 1995 | 67 | 0.030 |
Why?
|
| Inflammation | 1 | 2020 | 618 | 0.030 |
Why?
|
| Metabolomics | 1 | 2015 | 81 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 2721 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 33 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 158 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2026 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 421 | 0.030 |
Why?
|
| Down-Regulation | 1 | 1995 | 435 | 0.030 |
Why?
|
| RNA | 1 | 2015 | 241 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 1995 | 308 | 0.030 |
Why?
|
| Liver | 1 | 1996 | 479 | 0.030 |
Why?
|
| Blotting, Western | 1 | 1995 | 859 | 0.030 |
Why?
|
| Overweight | 1 | 2015 | 247 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1371 | 0.030 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2012 | 10 | 0.030 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 26 | 0.030 |
Why?
|
| Electrophoresis, Microchip | 1 | 2012 | 21 | 0.030 |
Why?
|
| Taxoids | 1 | 2012 | 37 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 571 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 1995 | 1518 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 400 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 550 | 0.020 |
Why?
|
| DNA Primers | 2 | 2004 | 286 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2005 | 14 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2005 | 60 | 0.020 |
Why?
|
| X Chromosome | 1 | 2004 | 30 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1997 | 1180 | 0.010 |
Why?
|
| Larva | 1 | 2004 | 124 | 0.010 |
Why?
|
| Genes, Suppressor | 1 | 2003 | 3 | 0.010 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2003 | 18 | 0.010 |
Why?
|
| DNA Replication | 1 | 2004 | 152 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2003 | 54 | 0.010 |
Why?
|
| Cell Line | 2 | 1997 | 1354 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 286 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 307 | 0.010 |
Why?
|
| Proline | 1 | 1997 | 43 | 0.010 |
Why?
|
| Trypsin | 1 | 1996 | 38 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1996 | 78 | 0.010 |
Why?
|
| Epithelium | 1 | 1996 | 79 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1996 | 188 | 0.010 |
Why?
|
| Transfection | 1 | 1996 | 523 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 448 | 0.010 |
Why?
|